Last updated: March 2026
Selank is a synthetic heptapeptide developed at Russia's Institute of Molecular Genetics. A modified analog of tuftsin, it allosterically modulates GABA-A receptors — delivering anxiolytic effects comparable to benzodiazepines without sedation, cognitive impairment, or addiction risk. Approved in Russia since 2009.
Selank operates through five overlapping neurochemical pathways. Unlike single-target drugs, this multi-system profile produces "clean" anxiolysis — calm clarity rather than sedated blunting.
Selank is a positive allosteric modulator of GABA-A receptors — the same receptor family targeted by benzodiazepines, but at a different binding site. Critically, it enhances GABAergic inhibition only in the presence of endogenous GABA, providing a built-in ceiling effect that prevents sedation and respiratory depression. Gene expression studies show 45 GABA-related genes altered within 1 hour of administration.
Selank inhibits enkephalin-degrading enzymes (enkephalinases), elevating plasma leu-enkephalin levels. Patients with generalized anxiety disorder exhibit shortened enkephalin half-life — Selank treatment significantly restored leu-enkephalin τ½ to normal values. Elevated endogenous opioids contribute to anxiolytic and mood-stabilizing effects (Sokolov et al., 2001, PMID: 11550013).
Selank influences serotonin, dopamine, and norepinephrine systems. Serotonergic effects contribute to mood stabilization; dopaminergic effects underlie the nootropic and psychostimulant qualities (cognitive enhancement beyond simple anxiety reduction). Meshavkin et al. (2006) confirmed dopamine and serotonin receptor modulation relevant to anxiety pathogenesis.
Selank upregulates BDNF mRNA expression in the hippocampus — a region central to emotional regulation and memory. Kolik et al. (2019, PMID: 31625062) showed Selank normalized pathologically elevated BDNF levels in rats during alcohol withdrawal and improved cognitive performance in aged non-alcoholic rats, suggesting neuroprotective activity.
As a tuftsin analog, Selank retains immunostimulatory properties. Yasenyavskaya et al. (2021) showed Selank normalized IL-1β, IL-6, TGF-β1, and TNF-α in a social stress model. Uchakina et al. (2008) demonstrated in vitro suppression of IL-6 gene expression in anxiety patients. Antiviral effects against influenza H3N2, HSV, and CMV have also been documented (Ershov et al., 2009).
Delivered intranasally, Selank accesses the brain via two routes: systemic absorption through nasal mucosa (bypassing first-pass metabolism) and direct olfactory nerve transport to the olfactory bulb — bypassing the blood-brain barrier entirely. Onset within 5–15 minutes; nasal bioavailability estimated at 70–90% for CNS-relevant delivery.
Evidence context: Selank has been approved and used clinically in Russia since 2009. It has a substantial peer-reviewed literature base spanning clinical RCTs, molecular pharmacology, and animal behavioral models going back to the early 1990s. The primary limitation is that most research is published in Russian journals with limited English translation, and no large-scale Western (FDA/EMA track) clinical trials exist.
Selank is primarily administered intranasally. The Russian approved formulation is a 0.15% solution (1.5 mg/mL). Research peptide vendors supply lyophilized powder for reconstitution. Subcutaneous injection is used in clinical research settings.
| Experience Level | Daily Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 200–300 mcg | Once daily | Start here to assess individual sensitivity |
| Intermediate | 400–600 mcg | 1–2× daily | Most common therapeutic range in practice |
| Advanced / Protocol | 600–900 mcg | 2–3× daily | Weight-adjusted; based on clinical protocols |
| Russian Clinical Standard | ~450 mcg | 3× daily | 2 drops/nostril × 3× at 0.15% solution, 14-day course |
| Body Weight | Men (mcg/day) | Women (mcg/day) | Frequency |
|---|---|---|---|
| Under 150 lbs | 200–400 | 150–300 | 1–2× daily |
| 150–200 lbs | 400–600 | 300–450 | 1–2× daily |
| 200+ lbs | 600–900 | 450–600 | 2–3× daily |
Selank and Semax work through overlapping neurotransmitter systems, so running them back-to-back in a structured rotation — rather than simultaneously — is the approach favored by most experienced researchers. The standard cycle alternates three-week blocks of each compound with one-week breaks for receptor reset.
| Week | Compound | Dose | Route | Primary Effect |
|---|---|---|---|---|
| 1–3 | Selank | 200–400 mcg/day | Intranasal | Anxiolytic, mood stabilization |
| 4 | Break | — | — | Receptor sensitivity reset |
| 5–7 | Semax | 200–600 mcg/day | Intranasal | Focus, memory, neuroprotection |
| 8 | Break | — | — | Receptor sensitivity reset |
The NA variant — N-Acetyl Selank Amidate — is a modified version of standard Selank with enhanced bioavailability at the nasal mucosa. The practical upshot: you need roughly 30–50% less to achieve equivalent effects compared to standard Selank. If you're dosing standard Selank at 300 mcg, start NA-Selank at 150–200 mcg and titrate from there. NA variants cost more per vial but can go further on a per-dose basis.
Selank has a well-documented favorable safety profile across three decades of Russian clinical use. Side effects are typically mild, transient, and primarily limited to the intranasal administration route.
How does Selank stack up against the standard-of-care options for anxiety? The 2008 RCT (Zozulia et al.) directly compared Selank to medazepam in GAD patients. Here's the full picture.
Cross-trial caveat: Direct comparisons below draw from multiple study populations. Studies were conducted at different times, in different populations, and with different methods. Comparisons are conceptual — not head-to-head clinical trial data except where noted.
| Property | Selank | Benzodiazepines | SSRIs/SNRIs | Buspirone |
|---|---|---|---|---|
| Anxiolytic Efficacy | High (comparable to benzo in RCT) | High | Moderate–High | Moderate |
| Onset of Action | 15–30 min (intranasal) | 30–60 min | 2–6 weeks | 2–4 weeks |
| Sedation | None observed | Common | Possible | Minimal |
| Cognitive Impairment | None (may enhance cognition) | Common (amnesia, fog) | Possible | Minimal |
| Physical Dependence | Not documented | High — develops in days/weeks | Discontinuation syndrome | None |
| Withdrawal Syndrome | Not documented | Severe — potentially dangerous | Moderate (SSRI discontinuation) | None |
| Psychostimulant / Nootropic Effect | Yes — antiasthenic, pro-cognitive | No — cognitive blunting | No | No |
| Immunomodulation | Yes — anti-inflammatory, antiviral | None / immunosuppressive | None significant | None |
| Regulatory Status (Russia) | Approved 2009 ✓ | Approved | Approved | Approved |
| Regulatory Status (USA) | Research compound only | Schedule IV (controlled) | FDA approved | FDA approved |
Third-party tested research compounds from Swiss Chems — lab certificates of analysis included with every order.
Affiliate links — supports MeetPeptide research content at no extra cost. All Swiss Chems products include third-party CoA.
Supplies for intranasal peptide use — reconstitution, administration, and storage.
Affiliate links help support MeetPeptide at no extra cost to you.
Selank is NOT FDA approved in the United States or approved by the EMA in the European Union. It is approved in Russia for anxiety and neurasthenia. This page is for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Do not use this information to make decisions about your health without consulting a qualified healthcare provider. Approved Russia 2009Research Compound — US/EU